Rozlytrek bags FDA approval
admin 16th August 2019 Uncategorised 0For the indication of ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
More: Rozlytrek bags FDA approval
Source: News
For the indication of ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
More: Rozlytrek bags FDA approval
Source: News
© 1994 - 2025 B.M. Pharmaceuticals